Core Viewpoint - Emei Mountain A is experiencing a recovery in visitor traffic, supported by shareholder rewards during the off-peak season, with expectations for improved capacity [1] Group 1: Visitor Traffic and Shareholder Rewards - During the New Year holiday from January 1 to January 3, 2026, the scenic area received 126,166 visitors, a 20.88% increase compared to the same period in 2024 [1] - Shareholder reward activities from December 1, 2025, to January 31, 2026, excluding statutory holidays, are expected to boost visitor traffic in December and January during non-holiday periods [1] Group 2: Capacity and Long-term Outlook - Improvements in transportation and capacity are anticipated, which will likely enhance long-term visitor traffic [1] - The company continues to provide cash dividends to shareholders, reflecting strong cash flow quality and a commitment to shareholder returns, which also aids in improving capital efficiency and investor return certainty [1] Group 3: Financial Forecast and Valuation - Due to weak revenue in 2025, the company has adjusted its EPS forecasts for 2025-2027 to 0.45, 0.54, and 0.61 yuan, down from previous estimates of 0.63 and 0.69 yuan for 2025-2026 [1] - Based on comparable companies, the target price for 2026 is set at 17.28 yuan, applying a 32x PE ratio, while maintaining a "buy" rating [1]

Group 1 - The core focus of the 2026 JPM Conference is on the strategic importance of IO (Immuno-Oncology) and ADC (Antibody-Drug Conjugates) in the oncology sector, with a significant emphasis on combination therapies [1] - The conference, held from January 12 to 15, 2026, in San Francisco, is recognized as a key event for insights into new drug development trends, capital flows, and business development collaborations in the healthcare industry [1] - Major multinational corporations (MNCs) are prioritizing second-generation IO and ADC, with a notable contribution from domestic innovations, particularly the introduction of sac-TMT by Merck as a focal point in oncology development [2] Group 2 - The exploration of combination therapies involving IO and ADC is accelerating, with multiple clinical trials underway, including 16 Phase III trials for sac-TMT and 4 Phase III trials for PD-(L)1/VEGF dual antibodies by Pfizer [2] - The year 2026 is identified as a pivotal year for the combination of IO and ADC, with expectations for increased demand for ADCs as they gain a core position in current cancer treatments [3] - Key players in the ADC market include companies such as Kangfang Biopharma, Sanofi, Rongchang Biopharma, and others, indicating a competitive landscape for ADC development [3]

一、本期业绩预告情况 （一）业绩预告期间 炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！ 证券代码：600958 证券简称：东方证券 公告编号：2026-003 东方证券股份有限公司 2025年年度业绩预增公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 重要内容提示： 1.业绩预告的具体适用情形：实现盈利，且净利润与上年同期相比上升50%以上。 2.东方证券股份有限公司（以下简称"公司"）预计2025年年度实现营业收入人民币153.4亿元，归属于母 公司所有者的净利润人民币56.2亿元，归属于母公司所有者的扣除非经常性损益的净利润人民币55.0亿 元。 2025年1月1日至2025年12月31日。 （二）业绩预告情况 经财务部门初步测算，公司2025年的经营业绩和财务状况如下： 1.预计2025年年度实现营业收入人民币153.4亿元，与上年同期相比，将增加人民币31.7亿元，同比增加 26.0%。（收入追溯情况说明：财政部于2025年7月8日发布标准仓单交易相关会计处理实施问答（以下 简称"问答 ...

（编辑 丛可心） 证券日报网讯 1月27日，东方证券发布公告称，公司预计2025年年度实现营业收入人民币153.4亿元，同 比增加26.0%；归属于母公司所有者的净利润人民币56.2亿元，同比增加67.8%。 ...

东方证券1月27日公告，预计2025年实现营业收入153.4亿元，同比增长26%；归母净利润56.2亿元，同 比增长67.80%。 ...

Core Viewpoint - Multiple listed securities firms are expected to report positive performance for 2025, with significant year-on-year profit growth anticipated across the sector [1][2]. Group 1: Performance Forecasts - Several securities firms, including China Merchants Securities, Shenwan Hongyuan Securities, Dongfang Securities, and Hongta Securities, have released performance forecasts indicating net profit growth of 18.43%, 74.64%-93.83%, 67.8%, and 59.05% respectively for 2025 [1][3]. - Citic Securities, a leading firm, reported a projected revenue of 748.3 billion yuan and a net profit of 300.51 billion yuan for 2025, reflecting year-on-year increases of 28.75% and 38.46% respectively [5][7]. - Dongfang Securities anticipates a revenue of 153.4 billion yuan, up 26.0%, and a net profit of 56.2 billion yuan, up 67.8% [4][7]. Group 2: Market Dynamics - The A-share market is expected to continue its upward trend, with daily trading volume increasing significantly, reaching an average of 19.8 trillion yuan, a 67% year-on-year increase [8]. - The balance of margin financing and securities lending is projected to reach 2.5 trillion yuan by the end of 2025, marking a 36% increase [8]. - Analysts attribute the strong performance of securities firms to three main factors: a stable macroeconomic environment, increased market activity, and strategic upgrades within firms [8][9]. Group 3: Analyst Predictions - Analysts predict that the overall net profit of listed securities firms will grow by over 50% in 2025, driven by robust trading activity and improved brokerage income [9][10]. - Financial Street Securities forecasts a 53.24% year-on-year increase in daily trading volume, with brokerage income expected to rise by over 40% [9]. - According to analysts, the growth in net profit is primarily driven by brokerage and investment business performance [10].

北京商报讯（记者 李海媛）1月27日，东方证券发布2025年年度业绩预增公告，预计2025年年度实现营 业收入153.4亿元，同比增26%；归属于母公司所有者的净利润56.2亿元，同比增67.8%。 ...

Group 1 - Heng Rui Medicine's HRS-5346 tablet has been included in the list of breakthrough therapeutic varieties by the National Medical Products Administration, with a total R&D investment of approximately 76.3 million yuan [2] - Yu Guang Jin Lead announced a significant stock price increase of 45.01% over five trading days, expressing uncertainty about the future price of silver [3] - Dongcai Technology's actual controller and vice chairman has been detained for investigation, but the company states that this will not significantly impact its normal operations [4] Group 2 - Aisen Co. plans to invest 2 billion yuan to establish an integrated circuit materials manufacturing base in East China, with the first phase expected to be operational by 2028 [5] - Jingpin Special Equipment has been banned from participating in procurement activities for three years, but the impact on overall operations is considered limited [6] - Nanhua Futures' overseas subsidiary has obtained membership at the Nodal Exchange, allowing it to trade and clear related products [7] Group 3 - Di'er Laser is planning to issue H-shares and apply for listing on the Hong Kong Stock Exchange to enhance its international strategy [8] - Zhong Rare Earth expects a net profit of 100 million to 130 million yuan in 2025, reversing a loss from the previous year due to market improvements [10] - Shen Nan Circuit anticipates a net profit increase of 68% to 78% in 2025, driven by demand in AI computing and smart automotive sectors [11] Group 4 - Hai Xin Energy Science and Technology expects a net loss of 450 million to 640 million yuan in 2025, although this is an improvement from the previous year's loss [12] - Nan Ya New Materials forecasts a net profit increase of 337% to 417% in 2025, attributed to a recovery in the copper-clad laminate industry [13] - CanSino expects a net profit of 24.5 million to 29 million yuan in 2025, driven by the growth of its quadrivalent meningococcal vaccine [14] Group 5 - Zhi Guang Electric anticipates a net profit of 110 million to 160 million yuan in 2025, reversing a previous loss due to growth in its energy storage business [15] - Dongfang Securities expects a net profit increase of 67.8% in 2025, benefiting from capital market opportunities [17] - Jinlong Automobile forecasts a net profit increase of 193.68% in 2025, supported by growth in overseas markets [18] Group 6 - Zhen Lei Technology expects a net profit increase of 529.64% to 642.26% in 2025, driven by demand in special integrated circuits [19] - Yong Ding Co. anticipates a net profit of 200 million to 300 million yuan in 2025, reflecting significant growth from investment income [20] - Xiamen Tungsten's preliminary report indicates a net profit of 2.311 billion yuan in 2025, a 35.08% increase year-on-year [21] Group 7 - Guo Dun Quantum expects a net profit of 5 million yuan in 2025, marking a return to profitability [22] - Shi Jia Photon forecasts a net profit increase of approximately 426% in 2025, driven by growth in optical chip orders [23] - Ningbo Fubang anticipates a net profit increase of 3099.59% to 4379.43% in 2025, largely due to rising silver prices and significant non-recurring gains [24] Group 8 - Huasheng Lithium Battery plans to adjust its share repurchase price limit from 32 yuan to 150 yuan per share [26] - Aonong Biological announced plans for multiple shareholders to reduce their stakes [28] - Pizaihuang's controlling shareholder intends to increase its stake by 300 million to 500 million yuan [29]

2025年公司抓住资本市场发展机遇，主动服务实体经济发展和社会财富管理，围绕一流现代投资银行建 设目标，扎实推进新三年战略规划实施。公司坚持稳中求进工作总基调，在大财富、大投行、大机构三 大领域持续发力，通过稳健经营与提质增效双轮驱动，实现规模、效益、质量的协同发展，经营发展呈 现良好态势。公司财富及资产管理、投行及另类投资、机构及销售交易、国际化等业务收入同比增长， 经营业绩同比实现较好增长。 智通财经APP讯，东方证券(600958.SH)发布2025年年度业绩预增公告，预计2025年年度实现归属于母 公司所有者的净利润人民币56.2亿元，与上年同期相比，将增加人民币22.7亿元，同比增加67.8%。 ...

免责声明：本文内容与数据仅供参考，不构成投资建议，使用前请核实。据此操作，风险自担。 （记者 曾健辉） 每经AI快讯，东方证券1月27日晚间发布业绩预告，预计2025年年度实现归属于母公司所有者的净利润 人民币56.2亿元，与上年同期相比，将增加人民币22.7亿元，同比增加67.8%。业绩变动主要原因是， 2025年公司抓住资本市场发展机遇，主动服务实体经济发展和社会财富管理，围绕一流现代投资银行建 设目标，扎实推进新三年战略规划实施。公司坚持稳中求进工作总基调，在大财富、大投行、大机构三 大领域持续发力，通过稳健经营与提质增效双轮驱动，实现规模、效益、质量的协同发展，经营发展呈 现良好态势。公司财富及资产管理、投行及另类投资、机构及销售交易、国际化等业务收入同比增长， 经营业绩同比实现较好增长。 每经头条（nbdtoutiao）——国际金价冲破5000美元！7年涨了280%，什么时候才见顶？专家：关键还 看美元，重点关注国际货币体系、降息和科技革命 ...